Yutrepia (treprostinil inhaled dry powder) / Liquidia Technologies - LARVOL DELTA

Simultaneous Liver-Kidney Transplantation in the Setting of Severe Port-Pulmonary Hypertension (ACG 2026) - "She was on tadalafil 40 mg daily and inhaled treprostinil 80 mcg; prior trials of selexipag and macitentan were discontinued due to intolerance and worsening anemia, respectively. Sotatercept was contraindicated given thrombocytopenia...Despite intolerance or contraindication to several standard pulmonary vasodilators, the patient was bridged to transplant with intravenous treprostinil, renal replacement therapy and careful volume management, to meet hemodynamic listing criteria. This case illustrates the importance of individualized, dynamic risk assessment in PoPH patients."

Cardiovascular • Fibrosis • Genetic Disorders • Hematological Disorders • Hepatology • Immunology • Nephrology • Polycystic Kidney Disease • Portal Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Thrombocytopenia • Thrombosis • Transplantation

An Early Single-Center Case Series Experience With a Recently Introduced Formulation of Inhaled Treprostinil (Yutrepia). (PubMed, Cureus) - " In this retrospective, single-center case series of Yutrepia, no airway-related dose modifications or discontinuations were documented; however, the 95% confidence interval (0.0%-14.9%) indicates that clinically relevant event rates cannot be excluded given the small sample size. Overall, however, 54.5% of patients experienced an adverse event, 40.9% required dose modification, and 36.4% discontinued treatment because of an adverse event. These findings should not be interpreted as indicating that Yutrepia was broadly well tolerated. The observed frequencies of airway-related adverse events were descriptively lower for some events than those reported in selected previous studies of inhaled treprostinil, but direct comparisons cannot be made because of differences in study populations, designs, follow-up, and adverse event ascertainment. Given the small sample size and retrospective design, these findings are hypothesis-generating, and larger prospective studies are..."

Journal • Cardiovascular • Cough • Fatigue • Hypertension • Hypotension • Interstitial Lung Disease • Pain • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Late Breaking Abstract - Inhaled Treprostinil does not improve exercise tolerance in patients with mild COPD (ERS 2026) - "iTRE decreased exercise tolerance in mild COPD without affecting ventilatory efficiency and dyspnea, while potentiating exercise blood pressure responses. These data suggest that iTRE is not a viable therapeutic target to improve functional capacity in mild COPD. Supported by United Therapeutics"

Clinical • Late-breaking abstract • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Late Breaking Abstract - The effect of inhaled treprostinil in patients with idiopathic pulmonary fibrosis using a win ratio analysis (ERS 2026) - "Win ratio analyses favored iTRE, confirming benefits in preventing CWE in patients with IPF, such as death, AE-IPF and RH."

Clinical • Late-breaking abstract • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Clinical and haemodynamic determinants of response to pulmonary vasodilators in pulmonary hypertension associated with interstitial lung disease (ERS 2026) - "With the exception of inhaled treprostinil, most trials of pulmonary vasodilators (PVDs) in PH-ILD have shown limited benefit. In PH-ILD, greater baseline PH severity is linked to greater PVR reduction on PVD therapy. While PVR reduction reflects improved 6MWD and WHO-FC, CI improvement serves as the key marker for survival. Baseline FVC was not associated with response, supporting the consideration of PVD therapy regardless of pulmonary function, provided that PH is severe."

Clinical • Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Survival in patients with pulmonary hypertension (PH) associated with interstitial lung diseases receiving therapies approved for PH (ERS 2026) - "This prospective study confirms the dismal prognosis of PH-ILD and does not suggest a one-year survival benefit from treatment with PDE5i or inhaled treprostinil."

Clinical • Cardiovascular • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Improvements in lung function among idiopathic pulmonary fibrosis patients treated with inhaled treprostinil (ERS 2026) - "Progressive FVC decline is a hallmark of IPF. Although a small proportion of patients stabilize or improve over time, treatment with inhaled treprostinil led to a greater proportion of patients experiencing an improvement in FVC at 52 weeks when compared to placebo. Table 1."

Clinical • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Patterns in interstitial lung disease: A snapshot of the baseline lung morphology in ILD-PH in the ASCENT study [NCT06129240] (ERS 2026) - P | "INTRODUCTION ASCENT is a prospective, open-label trial evaluating safety & tolerability of LIQ861 (YUTREPIA®) treprostinil inhalation powder in PH-ILD...Shlobin OA, et al. Eur Res J 2008"

Fibrosis • Immunology • Infectious Disease • Interstitial Lung Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

The acute effects of treprostinil dry powder inhaler on stroke volume augmentation and dead space ventilation in patients with exercise-induced pulmonary hypertension (ERS 2026) - "Inhaled treprostinil given 30 minutes before exercise improved stroke volume augmentation in EiPH. Phase 2, completing March 2026, will clarify effects on symptoms and physiologic response at maximally tolerated dosing."

Clinical • Cardiovascular • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Effect of inhaled treprostinil dosing in patients with idiopathic pulmonary fibrosis enrolled in the TETON IPF program (ERS 2026) - "Patients with IPF receiving doses of 9 bps or more of iTRE experienced greater improvement in FVC. These findings are consistent with prior dose response analyses of iTRE and align with currently approved dosing recommendations. Sponsored by United Therapeutics Corporation"

Clinical • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

INHALED TREPROSTINIL IN PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE: A SYSTEMATIC REVIEW (CHEST 2026) - No abstract available

Review • Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

7112: Time to Look Closer: Emerging Data and Screening Insights in PH-ILD (CHEST 2026) - "This session will spotlight screening considerations and explore how providers can apply these insights in practice. Attendees will also review the clinical data for inhaled treprostinil in PH-ILD and examine how earlier recognition may create more opportunities to support patient care."

Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

7105: YUTREPIA® (treprostinil) Inhalation Powder: A Prostacyclin Treatment for Your PAH and PH-ILD Patients (CHEST 2026) - "Sponsored by Liquidia Technologies, Inc. Description This presentation will explore YUTREPIA, the first and only dry powder formulation of treprostinil enabled by PRINT Technology approved for the treatment of patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)."

Clinical • Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

ASSOCIATION OF HEART RATE RECOVERY AND TREATMENT RESPONSE WITH INHALED TREPROSTINIL IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (CHEST 2026) - No abstract available

Clinical • Cardiovascular • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

FROM BENCH TO BREATH WITH INHALED TREPROSTINIL POWDER: AN EARLY SINGLE-CENTER CASE SERIES CLINICAL EXPERIENCE (CHEST 2026) - No abstract available

Clinical • Cardiovascular

EFFICACY OF INHALED TREPROSTINIL ON MULTIPLE DISEASE PROGRESSION EVENTS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS IN THE TETON-IPF PROGRAM (CHEST 2026) - No abstract available

Clinical • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

INHALED DRY POWDER FORMULATION OF TREPROSTINIL (LIQ861) IN PATIENTS WITH ILD-PH WITH LESS SEVERE HEMODYNAMICS: A SUBGROUP ANALYSIS OF THE ASCENT STUDY [NCT06129240] (CHEST 2026) - P | No abstract available

Clinical • Interstitial Lung Disease

COUNTERPRODUCTIVE VASODILATION: INHALED TREPROSTINIL AND VÃá/QÃá MISMATCH IN MIXED PH-COPD/ILD (CHEST 2026) - No abstract available

Chronic Obstructive Pulmonary Disease • Immunology • Interstitial Lung Disease • Respiratory Diseases

HEMODYNAMIC RECOVERY IN SEVERE PORTOPULMONARY HYPERTENSION WITH DRY POWDER INHALED TREPROSTINIL (CHEST 2026) - No abstract available

Cardiovascular • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

1489: Exploring Single and Combination Therapies in IPF: Better Together? (CHEST 2026) - "Positive findings from nerandomilast and treprostinil studies, a steady pipeline of antifibrotic clinical trials, and a bevy of anti-inflammatory medications provide clinicians numerous treatment options; however, current literature provides little guidance on how and when to implement these therapies, oftentimes leading to uncertainty when one's ILD progresses. 3. Recognize the outcomes associated with inhaled treprostinil in patients with ILD with and without pulmonary hypertension."

Combination therapy • Cardiovascular • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag (clinicaltrials.gov) - P4 | N=20 | Not yet recruiting | Sponsor: Liquidia Technologies, Inc.

New P4 trial • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

RE-WARM: A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks (clinicaltrials.gov) - P2 | N=75 | Not yet recruiting | Sponsor: Liquidia Technologies, Inc.

New P2 trial • Cardiovascular • Immunology • Rheumatology • Scleroderma • Systemic Sclerosis

ASCENT: An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH (clinicaltrials.gov) - P=N/A | N=80 | Recruiting | Sponsor: Liquidia Technologies, Inc. | Active, not recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Safety and Exploratory Efficacy data of LIQ861 Dry Powder Inhaled Treprostinil in PH-ILD patients: ASCENT to Week 24 (PHA 2026) - P | "LIQ861 was well tolerated over 24 weeks, with most patients titrating to =185.5 mcg QID (comparable to ~21 breaths nebulized treprostinil). Most common TEAE was mild cough with no change in simplified cough score. In patients with PHILD, LIQ861 improved exercise capacity (+41 m) from baseline over 24 weeks."

Clinical • Cough • Immunology • Infectious Disease • Inflammation • Interstitial Lung Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Hearing from Patients: Self-Reported Cough Outcomes During Treatment with YUTREPIA™ (treprostinil) in the ASCENT Trial (PHA 2026) - P | "Including the patients’ experience during clinical trials is important to gain a comprehensiveunderstanding of data interpretation. According to the Interim data in the ASCENT trial, patients withPH-ILD reported that their daytime cough severity remained stable and did not worsen during 24 weeksof treatment with YUTREPIA® (treprostinil) inhalation powder via DPI, even as doses were titratedupward. This patient-centered assessment complements investigator-reported AE data and offersreassurance to patients and clinicians: despite the known cough burden associated with ILD and historicalconcerns about DPI administration in this population, patients did not experience a meaningful worseningof their cough during treatment."

Clinical • Cardiovascular • Cough • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases